The global xeljanz tofacitnib market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor for the growth of the market is the increase in the number of arthritis patients which include patients suffering from rheumatoid arthritis, psoriatic arthritis, and ulcerative arthritis. According to the Global RA Network, around 350 million people across the globe are suffering from arthritis. Arthritis caused the US healthcare system to spend around $303 billion each year, according to the data submitted by the Centers for Disease Control and Prevention (CDC). This, in turn, is driving the demand for xeljanz tofacitnib drugs for the treatment of arthritis patients.

Free Sample Copy @ https://www.omrglobal.com/request-sample/xeljanz-tofacitnib-drug-market

The drug is marketed under the name of Xeljanz by Pfizer; it is a Janus kinases drug. The drug targets the reduction of inflammation caused by rheumatoid arthritis, by inhibiting the janus kinases which is involved in the inflammatory response pathway. In August 2021, the European Commission (EC) had approved the drug for the treatment of arthritis in Europe, which will further increase the demand for these drugs.

A Full Report of Global Xeljanz Tofacitnib Drug Market is Available at:
https://www.omrglobal.com/industry-reports/xeljanz-tofacitnib-drug-market

In addition to this, the EC has also approved the prolonged-release 11 mg version of the drug for the treatment of patients suffering from JPsA (juvenile psoriatic arthritis). In August 2021, Zydus Cadila, which is a part of Cadila Healthcare, received the final approval for the 180- days exclusivity for Xeljianz generic in the US.

Global Xeljanz Tofacitnib Drug Market – Segmentation
By Type
Tablets
Extended-Release Tablets
By Application
Rheumatoid Arthritis
Psoriatic Arthritis
Other

Global Xeljanz Tofacitnib Drug Market – Segmentation by Region 
North America 
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific 
China
Japan
India
Rest of Asia-Pacific
Rest of the World

Company Profiles
Novartis Inc.
Eli Lilly
Pfizer Inc.
AbbVie
Zydus Cadila
Teva Pharmaceuticals
Cipla
Natco Pharma
Intas Biopharmaceuticals

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/xeljanz-tofacitnib-drug-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404